Kudo S, Miyamoto G, Kawano K
Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Japan.
J Interferon Cytokine Res. 1999 Apr;19(4):361-7. doi: 10.1089/107999099314063.
The in vitro metabolic degradation of human interleukin (IL)-1beta was studied using lysates of rat kidney lysosomes, and proteases involved in the degradation were identified. In the study of IL-1beta degradation, fluorescein isothiocyanate (FITC)-labeled IL-1beta was used as a substrate. The maximal degradation of IL-1beta occurred at pH 3.0, and the reaction was proportional to the lysosomal protein concentration and time of incubation. The degradation was stimulated by the addition of L-cysteine. The reaction was not inhibited by phenylmethanesulfonyl fluoride or EDTA, indicating that serine proteases or metalloproteases do not play a major role in the degradation process. N-Ethylmaleimide, leupeptin and E-64, inhibitors of thiol protease, inhibited the degradation of IL-1beta, by 59%-70%. Pepstatin A, an inhibitor of carboxyl protease, inhibited the degradation by 58%. Combinations of thiol and carboxyl protease inhibitors nearly completely inhibited the degradation. Bio-Gel P-10 gel filtration chromatography of in vitro reactants confirmed the ability of lysosomal proteases to degrade IL-1beta and revealed four to five peaks of degradation products. Taken together, these results indicate that thiol protease and carboxyl protease play an important role in the IL-1beta degradation process by kidney lysosomes. Leupeptin and E-64 dose dependently inhibited both cathepsin B and cathepsin L activities, and pepstatin A strongly inhibited cathepsin D activity in rat kidney lysosomes. The present results suggest that cathepsin B, cathepsin L, and cathepsin D in kidney lysosomes are involved in the metabolic degradation of human IL-1beta.
利用大鼠肾脏溶酶体裂解物研究了人白细胞介素(IL)-1β的体外代谢降解,并鉴定了参与降解的蛋白酶。在IL-1β降解研究中,使用异硫氰酸荧光素(FITC)标记的IL-1β作为底物。IL-1β的最大降解发生在pH 3.0时,反应与溶酶体蛋白浓度和孵育时间成正比。添加L-半胱氨酸可刺激降解。该反应不受苯甲磺酰氟或EDTA抑制,表明丝氨酸蛋白酶或金属蛋白酶在降解过程中不起主要作用。硫醇蛋白酶抑制剂N-乙基马来酰亚胺、亮抑酶肽和E-64可抑制IL-1β的降解,抑制率为59%-70%。羧基蛋白酶抑制剂胃酶抑素A可抑制降解58%。硫醇和羧基蛋白酶抑制剂的组合几乎完全抑制了降解。对体外反应物进行Bio-Gel P-10凝胶过滤层析,证实了溶酶体蛋白酶降解IL-1β的能力,并揭示了四到五个降解产物峰。综上所述,这些结果表明硫醇蛋白酶和羧基蛋白酶在肾脏溶酶体对IL-1β的降解过程中起重要作用。亮抑酶肽和E-64剂量依赖性地抑制大鼠肾脏溶酶体中组织蛋白酶B和组织蛋白酶L的活性,胃酶抑素A强烈抑制组织蛋白酶D的活性。目前的结果表明,肾脏溶酶体中的组织蛋白酶B、组织蛋白酶L和组织蛋白酶D参与了人IL-1β的代谢降解。